Novel therapies – IMID Co-morbidities

Cardiovascular diseases (CVD) and metabolic syndrome are common in patients with immune-mediated inflammatory diseases (IMID). These conditions exhibit significant interactions, between diseases and in relation to treatments, highlighting the need for rheumatologists to take an active role in their management. It is now known that inflammation mediated by adipokines is important in the pathogenesis of obesity and cardiovascular-kidney-metabolic (CKM) syndrome. Novel therapeutics developed for metabolic comorbidities have demonstrated pleiotropic benefit across a range of diseases. Some of them even possess anti-inflammatory and immuno-modulatory effects, serving as adjuncts to the management of IMID. On the other hand, anti-inflammatory drugs have been rigorously tested for their efficacy in CVD and colchicine has become the first anti-inflammatory drug approved for this purpose. This paper will focus on the novel therapeutics and new purposes of conventional drugs in the management of CVD and metabolic syndrome, with additional discussion of their relevance in IMID.